Effect of different strength of intralesional triamcinolone acetonide in alopecia areata.

Comparison of efficacy and safety of intralesional triamcinolone acetonide at different strength in treatment of alopecia areata: A Randomized Controlled Trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063138

Enrollment

150

Registered

2024-02-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: triamcinolone acetonide: Injection triamcinolone acetonide 5 mg/ml injected into randomly assigned quadrants of alopecia areata once monthly for 4 months. Control Intervention1: triamci

Eligibility

Inclusion criteria

Inclusion criteria: 1. All clinically diagnosed cases of alopecia areata with duration of illness more than 4 months.

Exclusion criteria

Exclusion criteria: 1. Patients with existing skin diseases affecting the scalp such as psoriasis or seborrheic dermatitis. 2. Patients with evidence of adrenal cortex abnormality. 3. Patients known to be HIV or hepatitis B, C positive or otherwise immunocompromised

Design outcomes

Primary

Measure	Time frame
Complete regrowth of hair.Timepoint: Complete regrowth of hair within 4 months of treatment period	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Ravinder Singh

Institute of Medical Sciences Banaras Hindu University

drsatyendraderma@gmail.com9198120582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026